The inactivation of human CYP2E1 by phenethyl isothiocyanate, a naturally occurring chemopreventive agent, and its oxidative bioactivation.
Phenethylisothiocyanate (PEITC), a naturally occurring isothiocyanate and potent cancer chemopreventive agent, works by multiple mechanisms, including the inhibition of cytochrome P450 (P450) enzymes, such as CYP2E1, that are involved in the bioactivation of carcinogens. PEITC has been reported to be a mechanism-based inactivator of some P450s. We describe here the possible mechanism for the inactivation of human CYP2E1 by PEITC, as well as the putative intermediate that might be involved in the bioactivation of PEITC. PEITC inactivated recombinant CYP2E1 with a partition ratio of 12, and the inactivation was not inhibited in the presence of glutathione (GSH) and not fully recovered by dialysis. The inactivation of CYP2E1 by PEITC is due to both heme destruction and protein modification, with the latter being the major pathway for inactivation. GSH-adducts of phenethyl isocyanate (PIC) and phenethylamine were detected during the metabolism by CYP2E1, indicating formation of PIC as a reactive intermediate following P450-catalyzed desulfurization of PEITC. Surprisingly, PIC bound covalently to CYP2E1 to form protein adducts but did not inactivate the enzyme. Liquid chromatography mass spectroscopy analysis of the inactivated CYP2E1 apo-protein suggests that a reactive sulfur atom generated during desulfurization of PEITC is involved in the inactivation of CYP2E1. Our data suggest that the metabolism of PEITC by CYP2E1 that results in the inactivation of CYP2E1 may occur by a mechanism similar to that observed with other sulfur-containing compounds, such as parathion. Digestion of the inactivated enzyme and analysis by SEQUEST showed that Cys 268 may be the residue modified by PIC.
Department of Pharmacology, University of Michigan Medical School, Ann Arbor, MI, USA.
Yasushi
Y
Yoshigae
Chitra
C
Sridar
Ute M
UM
Kent
Paul F
PF
Hollenberg
D016588:Anticarcinogenic Agents / Q000493:pharmacokinetics* / Q000494:pharmacology*; D001711:Biotransformation; D065691:Cytochrome P-450 CYP2E1 Inhibitors; D006801:Humans; D066298:In Vitro Techniques; D017953:Isocyanates / Q000494:pharmacology; D017879:Isothiocyanates / Q000493:pharmacokinetics* / Q000494:pharmacology*; D008862:Microsomes, Liver / Q000187:drug effects / Q000378:metabolism; D010084:Oxidation-Reduction
D016588:Anticarcinogenic Agents; D065691:Cytochrome P-450 CYP2E1 Inhibitors; D017953:Isocyanates; D017879:Isothiocyanates; C058305:phenethyl isothiocyanate